Epigenetically silenced KAT2B suppresses de novo lipogenesis through destroying HDAC5/LSD1 complex assembly in renal cell carcinoma
Our findings reveal that KAT2B suppresses de novo lipogenesis by interfering with HDAC5-LSD1 complex assembly, and highlight the potential of FASN inhibitors as a therapeutic strategy for RCC patients with low KAT2B expression.
Authors
- Yuenan Liu (ORCID: https://orcid.org/0000-0002-4635-0634)
- Zirui Dong (ORCID: https://orcid.org/0000-0001-7295-0257)
- Daojia Miao (ORCID: https://orcid.org/0000-0002-7780-1282)
- Keshan Wang (ORCID: https://orcid.org/0000-0002-4128-2214)
- Qi Wang (ORCID: https://orcid.org/0000-0002-5287-6050)
- Xiaoping Zhang (ORCID: https://orcid.org/0000-0003-0218-3288)
- Chao Yang (ORCID: https://orcid.org/0000-0003-1714-3959)
- Ruijie Liu (ORCID: https://orcid.org/0000-0002-1489-1022)
- Zhiyong Xiong
- Mingfeng Li (ORCID: https://orcid.org/0000-0002-7959-6008)
- Hongmei Yang (ORCID: https://orcid.org/0009-0003-6352-9067)
Institutions
- Chinese Academy of Sciences (CN)
- Tianjin Institute of Industrial Biotechnology (CN)
- Union Hospital (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Advanced Research
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1016/j.jare.2025.08.007
- Citations
- 1
- Primary Topic
- Cancer, Lipids, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94